These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 16218488)
41. [Cardiovascular and gastrointestinal safety of NSAIDs]. van den Bemt P; Tjwa ET; van Oijen MG Ned Tijdschr Geneeskd; 2014; 158():A7311. PubMed ID: 24713339 [TBL] [Abstract][Full Text] [Related]
42. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective. Hochberg MC Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246 [TBL] [Abstract][Full Text] [Related]
43. Systematic review: coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients? Nielsen OH; Ainsworth M; Csillag C; Rask-Madsen J Aliment Pharmacol Ther; 2006 Jan; 23(1):27-33. PubMed ID: 16393277 [TBL] [Abstract][Full Text] [Related]
44. The murky waters of the coxibs: a review of the current state of play. Ostor AJ; Hazleman BL Inflammopharmacology; 2005; 13(4):371-80. PubMed ID: 16354390 [TBL] [Abstract][Full Text] [Related]
49. Hepatotoxicity induced by coxibs: how concerned should we be? Bessone F; Hernandez N; Roma MG; Ridruejo E; Mendizabal M; Medina-Cáliz I; Robles-Díaz M; Lucena MI; Andrade RJ Expert Opin Drug Saf; 2016 Nov; 15(11):1463-1475. PubMed ID: 27537326 [TBL] [Abstract][Full Text] [Related]
50. The effects of COX-2 anti-inflammatory drugs on soft tissue healing: a review of the literature. Randelli P; Randelli F; Cabitza P; Vaienti L J Biol Regul Homeost Agents; 2010; 24(2):107-14. PubMed ID: 20487623 [TBL] [Abstract][Full Text] [Related]
51. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. Borer JS; Simon LS Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S14-22. PubMed ID: 16168077 [TBL] [Abstract][Full Text] [Related]
52. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs. Joshi GP; Gertler R; Fricker R Anesth Analg; 2007 Dec; 105(6):1793-804, table of contents. PubMed ID: 18042885 [TBL] [Abstract][Full Text] [Related]
53. [Problems of cardiovascular toxicity of coxibs and non-selective NSA]. Forejtová S Vnitr Lek; 2006; 52(7-8):677-85. PubMed ID: 16967608 [TBL] [Abstract][Full Text] [Related]
54. Coxibs: is there a benefit when compared to traditional non-selective NSAIDs in postoperative pain management? Wickerts L; Warrén Stomberg M; Brattwall M; Jakobsson J Minerva Anestesiol; 2011 Nov; 77(11):1084-98. PubMed ID: 21617597 [TBL] [Abstract][Full Text] [Related]
55. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis. Wang X; Tian HJ; Yang HK; Wanyan P; Peng YJ Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):876-80. PubMed ID: 21900785 [TBL] [Abstract][Full Text] [Related]
57. Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal. Hinz B; Renner B; Brune K Nat Clin Pract Rheumatol; 2007 Oct; 3(10):552-60; quiz 1 p following 589. PubMed ID: 17906610 [TBL] [Abstract][Full Text] [Related]
58. Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor. Mukherjee D Thromb Haemost; 2006 Oct; 96(4):407-12. PubMed ID: 17003915 [TBL] [Abstract][Full Text] [Related]
59. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. Tannenbaum H; Bombardier C; Davis P; Russell AS; J Rheumatol; 2006 Jan; 33(1):140-57. PubMed ID: 16331802 [TBL] [Abstract][Full Text] [Related]